Drug intelligence / Profile preview

CF-108

Development stage: Preclinical
Lead developer: Zhongke CELFULL

Overview

CF-108 is a nutraceutical candidate being developed by Zhongke CELFULL Mitochondrial Medicine, specifically targeting aging. It is currently in the technical development (TechDev) phase of the company's nutraceutical pipeline. While specific molecular targets or mechanisms of action have not been publicly disclosed, the product is part of a portfolio focused on mitochondrial medicine, suggesting it may work by supporting mitochondrial health or cellular energy metabolism to address age-related decline.

Beyond the preview

Go deeper on CF-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF-108.

Explore the full profile